[HTML][HTML] Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly …
Journal of clinical oncology, 2010•ncbi.nlm.nih.gov
Purpose Immunologic targeting of tumor-specific gene mutations may allow precise
eradication of neoplastic cells without toxicity. Epidermal growth factor receptor variant III
(EGFRvIII) is a constitutively activated and immunogenic mutation not expressed in normal
tissues but widely expressed in glioblastoma multiforme (GBM) and other neoplasms.
eradication of neoplastic cells without toxicity. Epidermal growth factor receptor variant III
(EGFRvIII) is a constitutively activated and immunogenic mutation not expressed in normal
tissues but widely expressed in glioblastoma multiforme (GBM) and other neoplasms.
Abstract
Purpose
Immunologic targeting of tumor-specific gene mutations may allow precise eradication of neoplastic cells without toxicity. Epidermal growth factor receptor variant III (EGFRvIII) is a constitutively activated and immunogenic mutation not expressed in normal tissues but widely expressed in glioblastoma multiforme (GBM) and other neoplasms.
ncbi.nlm.nih.gov